^
    3d
    NCI-2018-00410: Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib)
    3d
    A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) (clinicaltrials.gov)
    P2, N=87, Completed, Eli Lilly and Company | Active, not recruiting --> Completed
    Trial completion
    |
    Jaypirca (pirtobrutinib)
    4d
    Ibrutinib enhances stem-cell-memory T cell generation during early T cell activation but inhibits T cell proliferation. (PubMed, Cell Immunol)
    In contrast, ibrutinib added 48 h post-activation did not show these effects. These findings suggest that caution should be exercised when incorporating ibrutinib into ex vivo expansion system for adoptive non-genetically engineered T cells or combining ibrutinib with these T cell immunotherapies in clinical trial settings.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CCR7 (Chemokine (C-C motif) receptor 7) • FAS (Fas cell surface death receptor) • IL15 (Interleukin 15) • IL7 (Interleukin 7)
    |
    Imbruvica (ibrutinib)
    4d
    A 3D lymph node model for chronic lymphocytic leukaemia recapitulates microenvironmental features and drug response in vitro. (PubMed, Dis Model Mech)
    Venetoclax treatment revealed greater CLL protection within the LN environment than in BM, whereas ibrutinib's mobilizing effect was comparable. This 3D LN model offers an effective ex vivo platform for studying microenvironment-tumour interactions and tissue-specific drug responses.
    Preclinical • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib)
    4d
    OPTIMIZE: HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis (clinicaltrials.gov)
    P2, N=313, Active, not recruiting, Center for International Blood and Marrow Transplant Research | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan
    4d
    Atalanta-1: A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=274, Active, not recruiting, Galapagos NV | Recruiting --> Active, not recruiting
    Enrollment closed
    4d
    Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1/2, N=66, Recruiting, National Cancer Institute (NCI) | N=132 --> 66
    Enrollment change
    |
    CD19 (CD19 Molecule)
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV
    5d
    Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformation. (PubMed, Blood Adv)
    Given the favorable toxicity profile of mosunetuzumab, and rapid and durable complete responses observed in this cohort, further investigation of mosunetuzumab for the treatment of RT, as monotherapy and in combination with other novel agents or chemotherapy, is warranted. NCT02500407.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Lunsumio (mosunetuzumab-axgb)
    7d
    PBCAR0191-01: Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)
    P1, N=135, Recruiting, Imugene Limited | Trial primary completion date: Jun 2025 --> Jun 2027
    Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • azercabtagene zapreleucel (PBCAR0191)
    7d
    Have Fixed-Duration (FD) Regimens Delivered on Their Promise in Chronic Lymphocytic Leukemia and What Is the Future of FD Regimens? A Narrative Review. (PubMed, Adv Ther)
    Successful fixed-duration regimens in CLL should achieve deep remission (i.e., undetectable minimal residual disease), sustain long-term progression-free survival, decrease the burden of treatment-related adverse events, and allow for re-treatment with minimal risk of drug resistance. Although fixed-duration treatment represents a positive step forward for most patients with CLL/SLL, the currently approved regimens often fall short in patients at high risk of progression. Continued research and development of next-generation drugs is essential to enhance efficacy and safety, ultimately improving outcomes in all patients with CLL/SLL.
    Review • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    IGH mutation
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    7d
    Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies (clinicaltrials.gov)
    P=N/A, N=38, Recruiting, University of Wisconsin, Madison | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    8d
    Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances (clinicaltrials.gov)
    P1/2, N=64, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting | N=11 --> 64
    Enrollment open • Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD5 (CD5 Molecule)
    |
    cyclophosphamide • fludarabine IV